Benitec Biopharma Inc. - 8-K Filing

Benitec Biopharma reports 100% responder rate in interim Phase 1b/2a clinical results for BB-301 treating OPMD-related dysphagia. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

3 articles from 1 source · updated October 30, 2026, 12:02 UTC

Coverage

• Vor Biopharma Inc. - 10-Q Filing SEC EDGAR · October 30, 2026, 12:02 UTC
• FIRST US BANCSHARES, INC. - 8-K Filing SEC EDGAR · October 28, 2026, 20:26 UTC
• Benitec Biopharma Inc. - 8-K Filing SEC EDGAR · October 28, 2026, 12:04 UTC